JP2012509340A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012509340A5 JP2012509340A5 JP2011537586A JP2011537586A JP2012509340A5 JP 2012509340 A5 JP2012509340 A5 JP 2012509340A5 JP 2011537586 A JP2011537586 A JP 2011537586A JP 2011537586 A JP2011537586 A JP 2011537586A JP 2012509340 A5 JP2012509340 A5 JP 2012509340A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- vaccine
- nos
- optimized
- polypeptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 claims description 69
- 229920001184 polypeptide Polymers 0.000 claims description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 42
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 42
- 230000003612 virological effect Effects 0.000 claims description 29
- 241000701161 unidentified adenovirus Species 0.000 claims description 17
- 108010067390 Viral Proteins Proteins 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 12
- 230000009385 viral infection Effects 0.000 claims description 11
- 208000031886 HIV Infections Diseases 0.000 claims description 10
- 241000700605 Viruses Species 0.000 claims description 8
- 208000036142 Viral infection Diseases 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 241000205701 Human adenovirus 26 Species 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 241000701124 Human adenovirus 35 Species 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 241000282412 Homo Species 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 241001430294 unidentified retrovirus Species 0.000 description 8
- 230000024932 T cell mediated immunity Effects 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 241000712891 Arenavirus Species 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 4
- 241000711950 Filoviridae Species 0.000 description 4
- 241000710831 Flavivirus Species 0.000 description 4
- 241000713112 Orthobunyavirus Species 0.000 description 4
- 241001631646 Papillomaviridae Species 0.000 description 4
- 241000709664 Picornaviridae Species 0.000 description 4
- 241001505332 Polyomavirus sp. Species 0.000 description 4
- 241000125945 Protoparvovirus Species 0.000 description 4
- 241000702263 Reovirus sp. Species 0.000 description 4
- 244000309743 astrovirus Species 0.000 description 4
- 241001529453 unidentified herpesvirus Species 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11570308P | 2008-11-18 | 2008-11-18 | |
| US61/115,703 | 2008-11-18 | ||
| US15218409P | 2009-02-12 | 2009-02-12 | |
| US61/152,184 | 2009-02-12 | ||
| US24818809P | 2009-10-02 | 2009-10-02 | |
| US61/248,188 | 2009-10-02 | ||
| PCT/US2009/064999 WO2010059732A1 (en) | 2008-11-18 | 2009-11-18 | Antiviral vaccines with improved cellular immunogenicity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015021128A Division JP6023233B2 (ja) | 2008-11-18 | 2015-02-05 | 細胞性免疫原性が向上した抗ウイルスワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012509340A JP2012509340A (ja) | 2012-04-19 |
| JP2012509340A5 true JP2012509340A5 (enExample) | 2013-12-19 |
| JP5694945B2 JP5694945B2 (ja) | 2015-04-01 |
Family
ID=42198483
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011537586A Expired - Fee Related JP5694945B2 (ja) | 2008-11-18 | 2009-11-18 | 細胞性免疫原性が向上した抗ウイルスワクチン |
| JP2015021128A Expired - Fee Related JP6023233B2 (ja) | 2008-11-18 | 2015-02-05 | 細胞性免疫原性が向上した抗ウイルスワクチン |
| JP2016198037A Expired - Fee Related JP6224197B2 (ja) | 2008-11-18 | 2016-10-06 | 細胞性免疫原性が向上した抗ウイルスワクチン |
| JP2017193941A Expired - Fee Related JP6368416B2 (ja) | 2008-11-18 | 2017-10-04 | 細胞性免疫原性が向上した抗ウイルスワクチン |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015021128A Expired - Fee Related JP6023233B2 (ja) | 2008-11-18 | 2015-02-05 | 細胞性免疫原性が向上した抗ウイルスワクチン |
| JP2016198037A Expired - Fee Related JP6224197B2 (ja) | 2008-11-18 | 2016-10-06 | 細胞性免疫原性が向上した抗ウイルスワクチン |
| JP2017193941A Expired - Fee Related JP6368416B2 (ja) | 2008-11-18 | 2017-10-04 | 細胞性免疫原性が向上した抗ウイルスワクチン |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US9017691B2 (enExample) |
| EP (2) | EP3470437A1 (enExample) |
| JP (4) | JP5694945B2 (enExample) |
| CN (1) | CN102282175B (enExample) |
| AP (1) | AP3719A (enExample) |
| AU (1) | AU2009316629B2 (enExample) |
| BR (2) | BR122021004758B1 (enExample) |
| CY (1) | CY1121215T1 (enExample) |
| DK (1) | DK2358757T3 (enExample) |
| ES (1) | ES2699685T3 (enExample) |
| HR (1) | HRP20181776T1 (enExample) |
| HU (1) | HUE042397T2 (enExample) |
| IL (2) | IL212984A (enExample) |
| LT (1) | LT2358757T (enExample) |
| NZ (2) | NZ593598A (enExample) |
| PL (1) | PL2358757T3 (enExample) |
| PT (1) | PT2358757T (enExample) |
| SG (1) | SG10201408784SA (enExample) |
| SI (1) | SI2358757T1 (enExample) |
| SM (1) | SMT201800631T1 (enExample) |
| WO (1) | WO2010059732A1 (enExample) |
| ZA (2) | ZA201104538B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3227814B2 (ja) | 1992-07-29 | 2001-11-12 | 三菱マテリアル株式会社 | スクラッププレス装置 |
| SMT202000101T1 (it) | 2008-10-10 | 2020-03-13 | Childrens Medical Center | Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente |
| PT2358757T (pt) * | 2008-11-18 | 2018-12-04 | Beth Israel Deaconess Medical Ct Inc | Vacinas antivirais com imunogenicidade celular melhorada |
| EP2620446A1 (en) * | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| CN105051198A (zh) | 2012-11-16 | 2015-11-11 | 貝丝以色列女执事医疗中心 | 重组腺病毒及其用途 |
| CN105263506B (zh) * | 2013-01-07 | 2018-03-09 | 贝丝以色列女执事医疗中心 | 稳定的人免疫缺陷病毒(HIV)包膜(EnV)三聚体疫苗及其使用方法 |
| US10376583B2 (en) | 2013-09-30 | 2019-08-13 | Beth Israel Deaconess Medical Center, Inc. | Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator |
| EP3052518B1 (en) | 2013-10-04 | 2020-01-08 | Beth Israel Deaconess Medical Center, Inc. | Stabilized human immunodeficiency virus (hiv) clade c envelope (env) trimer vaccines and methods of using same |
| CA2926025A1 (en) | 2013-10-07 | 2015-04-16 | The Trustees Of The University Of Pennsylvania | Vaccines with interleukin-33 as an adjuvant |
| JP6769869B2 (ja) * | 2013-10-16 | 2020-10-14 | ニユー・イングランド・バイオレイブス・インコーポレイテツド | 強化された特性を有する逆転写酵素 |
| WO2015128421A1 (en) * | 2014-02-28 | 2015-09-03 | Crucell Holland B.V. | Replicating recombinant adenovirus vectors, compositions, and methods of use thereof |
| CA2961024A1 (en) | 2014-09-26 | 2016-03-31 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for inducing protective immunity against human immunodeficiency virus infection |
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| EP3212209A4 (en) * | 2014-10-27 | 2018-10-03 | Academia Sinica | Plant defense signaling peptides and applications thereof |
| WO2016196471A1 (en) | 2015-06-02 | 2016-12-08 | Cooper Human Systems Llc | Methods and compositions for treatment of hiv infection |
| US10542961B2 (en) | 2015-06-15 | 2020-01-28 | The Research Foundation For The State University Of New York | System and method for infrasonic cardiac monitoring |
| US10758609B2 (en) * | 2015-09-25 | 2020-09-01 | University Of Florida Research Foundation, Inc. | Cross-reactive T-cell epitopes of HIV, SIV, and FIV for vaccines in humans and cats |
| CA3008542C (en) * | 2015-12-15 | 2020-06-02 | Janssen Vaccines & Prevention B.V. | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof |
| JP6595132B2 (ja) | 2016-06-16 | 2019-10-23 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Ｈｉｖワクチン製剤 |
| CN110494159A (zh) | 2016-09-02 | 2019-11-22 | 扬森疫苗与预防公司 | 在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法 |
| SG10202001956UA (en) | 2016-09-15 | 2020-04-29 | Janssen Vaccines & Prevention Bv | Trimer stabilizing hiv envelope protein mutations |
| WO2018075559A1 (en) | 2016-10-17 | 2018-04-26 | Beth Israel Deaconess Medical Center, Inc. | Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same |
| EP3638302B1 (en) | 2017-06-15 | 2024-03-13 | Janssen Vaccines & Prevention B.V. | Poxvirus vectors encoding hiv antigens, and methods of use thereof |
| MY200554A (en) | 2017-07-19 | 2024-01-03 | Janssen Vaccines & Prevention Bv | Trimer stabilizing hiv envelope protein mutations |
| WO2019018724A1 (en) | 2017-07-21 | 2019-01-24 | Janssen Vaccines & Prevention B.V. | METHODS FOR SAFE INDUCTION OF MULTICLADED CROSS-IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HUMAN BEINGS |
| WO2019055888A1 (en) | 2017-09-18 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT |
| WO2019118480A1 (en) | 2017-12-11 | 2019-06-20 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and uses thereof |
| EP3797118A4 (en) | 2018-05-22 | 2022-06-29 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| AU2019345942A1 (en) | 2018-09-25 | 2021-03-18 | Janssen Vaccines & Prevention B.V. | Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components |
| US12459989B2 (en) | 2018-11-21 | 2025-11-04 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (HIV) |
| WO2020237052A1 (en) | 2019-05-22 | 2020-11-26 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| EP3999107A1 (en) | 2019-07-16 | 2022-05-25 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| EP4058058A1 (en) | 2019-11-14 | 2022-09-21 | Aelix Therapeutics S.L. | Dosage regimens for vaccines |
| CN116096732A (zh) | 2020-01-31 | 2023-05-09 | 贝斯以色列护理医疗中心有限公司 | 用于预防和治疗冠状病毒感染的组合物和方法-sars-cov-2疫苗 |
| JP2023521837A (ja) * | 2020-04-14 | 2023-05-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 大きな配列の汎コロナウイルスワクチン組成物 |
| CA3182703A1 (en) | 2020-05-12 | 2021-11-18 | Janssen Vaccines & Prevention B.V. | Administration of homologous adenoviral vectors |
| US20220118081A1 (en) | 2020-10-20 | 2022-04-21 | Janssen Vaccines & Prevention B.V. | HIV vaccine regimens |
| US12053517B2 (en) | 2021-01-14 | 2024-08-06 | Gilead Sciences, Inc. | HIV vaccines and methods of using |
| CN116867517A (zh) | 2021-02-23 | 2023-10-10 | 扬森疫苗与预防公司 | 三聚体稳定性hiv包膜蛋白突变 |
| WO2023156505A1 (en) | 2022-02-17 | 2023-08-24 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l |
| WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
| EP4661878A2 (en) * | 2023-02-07 | 2025-12-17 | Merck Sharp & Dohme LLC | Adjuvant formulations including low viscosity chitosan or chitosan derivatives |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
| AU672359B2 (en) | 1991-03-07 | 1996-10-03 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
| US20050232900A1 (en) | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| CA2422882A1 (en) * | 2000-09-15 | 2002-03-21 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications |
| US20040101957A1 (en) * | 2001-09-14 | 2004-05-27 | Emini Emilio A. | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications |
| US7195768B2 (en) | 2001-11-07 | 2007-03-27 | Duke University | Polyvalent immunogen |
| US7172761B2 (en) | 2001-11-07 | 2007-02-06 | Duke University | Polyvalent immunogen |
| WO2003039470A2 (en) | 2001-11-07 | 2003-05-15 | Duke University | Polyvalent immunogen of hiv |
| US20030219452A1 (en) | 2001-11-27 | 2003-11-27 | Haynes Barton F. | HIV envelope V3-CCR5 binding site immunogen |
| WO2004001032A2 (en) | 2002-04-25 | 2003-12-31 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
| US20080153083A1 (en) | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
| EP1553983A2 (en) | 2002-10-23 | 2005-07-20 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
| US20050221493A1 (en) | 2002-12-04 | 2005-10-06 | Crucell Holland B.V. | Recombinant virus production for the manufacturing of vaccines |
| JP4773352B2 (ja) | 2003-09-17 | 2011-09-14 | デューク ユニバーシティ | コンセンサス／先祖免疫原 |
| US20070298051A1 (en) | 2003-11-19 | 2007-12-27 | Beth Israel Deaconess Medical Center | Adjuvants Of Immune Response |
| US7741099B2 (en) | 2004-10-13 | 2010-06-22 | Beth Israel Deaconess Medical Center Inc. | Adenoviral vectors and uses thereof |
| NZ555907A (en) | 2004-11-16 | 2009-12-24 | Aeras Global Tb Vaccine Found | Multivalent vaccines comprising recombinant viral vectors |
| US7951377B2 (en) | 2005-08-23 | 2011-05-31 | Los Alamos National Security, Llc | Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens |
| AU2006283101B2 (en) | 2005-08-23 | 2013-03-07 | Beth Israel Deaconess Medical Center | Polyvalent vaccine |
| WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| WO2008140579A2 (en) | 2006-11-17 | 2008-11-20 | New York University | Induction of broadly reactive neutralizing antibodies by focusing the immune response on v3 epitopes of the hiv-1 gp120 envelope |
| WO2008118470A2 (en) | 2007-03-27 | 2008-10-02 | The Regents Of The University Of California | Acute transmitted hiv envelope signatures |
| WO2010042817A1 (en) * | 2008-10-10 | 2010-04-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of hiv mosaic envelope proteins to optimize t-cell responses against hiv envelope |
| PT2358757T (pt) * | 2008-11-18 | 2018-12-04 | Beth Israel Deaconess Medical Ct Inc | Vacinas antivirais com imunogenicidade celular melhorada |
| WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
| US9017961B2 (en) | 2012-03-05 | 2015-04-28 | E.I. Du Pont De Nemours And Company | Recombinant bacteria comprising novel sucrose transporters |
-
2009
- 2009-11-18 PT PT09828172T patent/PT2358757T/pt unknown
- 2009-11-18 SM SM20180631T patent/SMT201800631T1/it unknown
- 2009-11-18 SG SG10201408784SA patent/SG10201408784SA/en unknown
- 2009-11-18 US US13/130,018 patent/US9017691B2/en active Active
- 2009-11-18 NZ NZ593598A patent/NZ593598A/xx not_active IP Right Cessation
- 2009-11-18 SI SI200931885T patent/SI2358757T1/sl unknown
- 2009-11-18 AP AP2011005767A patent/AP3719A/en active
- 2009-11-18 CN CN200980154787.4A patent/CN102282175B/zh not_active Expired - Fee Related
- 2009-11-18 NZ NZ60250409A patent/NZ602504A/en not_active IP Right Cessation
- 2009-11-18 BR BR122021004758-8A patent/BR122021004758B1/pt active IP Right Grant
- 2009-11-18 AU AU2009316629A patent/AU2009316629B2/en not_active Ceased
- 2009-11-18 ES ES09828172T patent/ES2699685T3/es active Active
- 2009-11-18 EP EP18191558.8A patent/EP3470437A1/en not_active Withdrawn
- 2009-11-18 LT LTEP09828172.8T patent/LT2358757T/lt unknown
- 2009-11-18 BR BRPI0921588-3A patent/BRPI0921588B1/pt not_active IP Right Cessation
- 2009-11-18 EP EP09828172.8A patent/EP2358757B1/en active Active
- 2009-11-18 JP JP2011537586A patent/JP5694945B2/ja not_active Expired - Fee Related
- 2009-11-18 WO PCT/US2009/064999 patent/WO2010059732A1/en not_active Ceased
- 2009-11-18 DK DK09828172.8T patent/DK2358757T3/da active
- 2009-11-18 HR HRP20181776TT patent/HRP20181776T1/hr unknown
- 2009-11-18 HU HUE09828172A patent/HUE042397T2/hu unknown
- 2009-11-18 PL PL09828172T patent/PL2358757T3/pl unknown
-
2011
- 2011-05-18 IL IL212984A patent/IL212984A/en active IP Right Grant
- 2011-06-20 ZA ZA2011/04538A patent/ZA201104538B/en unknown
-
2012
- 2012-07-04 ZA ZA2012/04999A patent/ZA201204999B/en unknown
-
2015
- 2015-02-05 JP JP2015021128A patent/JP6023233B2/ja not_active Expired - Fee Related
- 2015-02-26 US US14/632,869 patent/US9670253B2/en active Active
-
2016
- 2016-02-07 IL IL243991A patent/IL243991B/en active IP Right Grant
- 2016-10-06 JP JP2016198037A patent/JP6224197B2/ja not_active Expired - Fee Related
-
2017
- 2017-04-17 US US15/489,220 patent/US10426831B2/en not_active Expired - Fee Related
- 2017-10-04 JP JP2017193941A patent/JP6368416B2/ja not_active Expired - Fee Related
-
2018
- 2018-12-10 CY CY20181101309T patent/CY1121215T1/el unknown
-
2019
- 2019-06-14 US US16/441,703 patent/US10772952B2/en not_active Expired - Fee Related
-
2020
- 2020-09-10 US US16/948,257 patent/US11331386B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012509340A5 (enExample) | ||
| JP6368416B2 (ja) | 細胞性免疫原性が向上した抗ウイルスワクチン | |
| US8137931B2 (en) | Fusion proteins of HIV regulatory/accessory proteins | |
| KR102020758B1 (ko) | 안정화된 사람 면역결핍 바이러스 (ｈｉｖ) 외피 (ｅｎｖ) 삼량체 백신 및 이의 사용 방법 | |
| JP2019526580A5 (enExample) | ||
| JP2013507107A5 (enExample) | ||
| JP2010539901A5 (enExample) | ||
| SG178909A1 (en) | Generation of a broad t-cell response in humans against hiv | |
| WO2007137591A8 (en) | Hiv vaccine | |
| WO2005052165A1 (ja) | 抗ヒト免疫不全ウイルス感染防御用キメラ５型/１１型もしくは３５型アデノウイルスベクター | |
| CN102258779A (zh) | 四种及四种以上hiv载体基因疫苗序贯及重复应用 |